Study in Patients With Asthma
NCT00215358 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2010-11-11
Summary
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.
Conditions
Interventions
- DRUG
-
Formoterol Fumarate
Sponsors & Collaborators
-
Dey
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 12 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-07-31
- Primary Completion
- 2002-10-31
- Completion
- 2005-12-31
Countries
- United States
Study Locations
More Related Trials
-
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
NCT01436071 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
NCT01431950 ·Status: COMPLETED ·Phase: PHASE3
-
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
NCT01537133 ·Status: COMPLETED ·Phase: NA
-
Asthma Comparative Effectiveness Study
NCT01623544 ·Status: COMPLETED
-
Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma
NCT00995800 ·Status: COMPLETED ·Phase: PHASE2
-
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
NCT00394121 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT01225913 ·Status: RECRUITING ·Phase: PHASE4
-
Study in Mild Asthmatic Patients
NCT00748306 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
NCT05850494 ·Status: COMPLETED ·Phase: PHASE3
-
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
NCT00393952 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
NCT00393991 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-Week Study in Adult Subjects With Asthma
NCT01516086 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MK0359 in Patients With Chronic Asthma (0359-013)
NCT00482898 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
NCT01085474 ·Status: COMPLETED
-
The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China
NCT01785901 ·Status: COMPLETED
-
Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.
NCT02811315 ·Status: WITHDRAWN
-
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study
NCT01018186 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
NCT05292586 ·Status: COMPLETED ·Phase: PHASE3
-
To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)
NCT01725685 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
NCT00411567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
NCT03086460 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
NCT00862394 ·Status: COMPLETED ·Phase: PHASE3
-
12-Week Study in Adult Subjects With Asthma
NCT01516073 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
NCT01641081 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications
NCT04185129 ·Status: UNKNOWN ·Phase: PHASE4